Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: July 2019

Rapid insights on clinical impact of ASCO – Integration of new treatment regimens in CLL

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 3rd OncoPoll™ study following the 2019 ASCO conference, we looked at the oral presentations in CLL and researched how US and EU5 oncologists evaluated them.

Click to enlarge

Even with these CLL presentations being on the last day of ASCO, the awareness and enthusiasm for the use of Venetoclax + Obinutuzumab, Acalabrutinib + Obinutuzumab, and the CD19-targeted CAR-T cell product Lisocabtagene Maraleucel does not seem to be dampened. In our full report, we examine how the efficacy and safety & tolerability profiles of each of these agents are viewed in relation to currently available treatment options and how these regimens will be integrated into clinical practice. As can be seen from the data excerpt, there is good reason to assume that the new regimens will be making quite an impact throughout the treatment process.

Click here to get a full copy of our complimentary MDoutlook OncoPoll report

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community – read our blog on this topic on their site.

Last week, we published our post-ASCO OncoPolls on early advanced prostate cancer (nmCRPC and mHSPC) and on novel targeted agents in mNSCLC.

If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.

Rapid insights on clinical impact of ASCO – Novel Targeted Agents for mNSCLC

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 2nd OncoPoll™ study following the 2019 ASCO conference, we researched what US and EU5 oncologists thought about a number of new agents being developed that target specific driver mutations in small populations of metastatic NSCLC patients (among other cancer types).

Click to enlarge

The awareness of these agents is already at a moderate level, higher than what one would normally expect for agents only in Phase 1 and/or Phase 2 clinical trials and broader than just the 40% of respondents who attended the Oral Abstract session at ASCO (see below). In our full report, we examine how the efficacy and safety & tolerability profiles of each of these agents are viewed in relation to currently available treatment options and even dive a little into how these agents are currently compared with each other.

Click here to get a full copy of our complimentary MDoutlook OncoPoll report.

Click to enlarge

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community – read our blog on this topic on their site. We just published our post-ASCO OncoPoll on prostate cancer and our 3rd post-ASCO reports on CLL will be available very soon.

If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.

Rapid insights on clinical impact of ASCO – What will happen in nmCRPC and mHSPC

After every major conference, MDoutlook provides valuable insights on the impact of new data presented. At the 2019 ASCO conference, prostate cancer was one of the hottest areas, and our 1st independent OncoPoll™ study researched how clinicians will be treating the non-metastatic castration-resistant and the metastatic hormone-sensitive prostate cancer (nmCRPC and mHSPC) populations based on the new data presented. The impact of ASCO is far and wide, so in this analysis, we compared how oncologists and urologists in the US and EU5 will be integrating the information into their clinical practices.

post ASCO nmCRPC mHSPC clinical insights MDoutlook

Click to enlarge

All 3 of the 2nd generation anti-androgens discussed during ASCO are seen as more efficacious than currently available treatment options (see figure). But how does this evaluation differ between oncologists and urologists in the US and EU5? Does this positive view extend to the safety profiles? Most importantly, how will these views translate into actual clinical decisions?

Click here to get a full copy of our complimentary MDoutlook OncoPoll report.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community –read our blog on this topic on their site. Be on the lookout for our additional post-ASCO reports on CLL and NSCLC coming soon.

If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.